miR-20a regulates expression of the iron exporter ferroportin in lung cancer by unknown
ORIGINAL ARTICLE
miR-20a regulates expression of the iron exporter ferroportin
in lung cancer
Kamesh R. Babu1,2 & Martina U. Muckenthaler1,2
Received: 24 August 2015 /Revised: 20 October 2015 /Accepted: 26 October 2015 /Published online: 12 November 2015
#
Abstract
Ferroportin (FPN) exports iron from duodenal enterocytes,
macrophages, and hepatocytes to maintain systemic iron ho-
meostasis. In addition, FPN is expressed in various cancer
cells. Here, we show that in lung cancer, FPN expression is
regulated by miR-20a. Within the FPN-3′-untranslated region
(3′UTR), we identify and experimentally validate three evolu-
tionarily conserved target sites for the microRNA (miRNA)
members of the miR-17 seed family, including miR-20a. Our
analysis of RNA sequencing data from patients with lung
adenocarcinoma (LUAD) and lung squamous cell carcinoma
(LUSC) revealed that FPN messenger RNA (mRNA) levels
are significantly decreased in tumor compared to matched
healthy tissue, while miR-20a levels are increased. A signifi-
cant negative correlation of miR-20a and FPN expression was
observed. Functional studies further demonstrate that FPN is
post-transcriptionally regulated by miR-20a in non-small cell
lung cancer (NSCLC) cells and that overexpression or knock-
down of miR-20a or FPN affects NSCLC proliferation and
colony formation. Taken together, our data suggest that in-
creased expression of miR-20 in lung cancer may decrease
iron export, leading to intracellular iron retention, which, in
turn, favors cell proliferation.
Key messages
& miR-20a controls expression of the iron exporter
ferroportin (FPN) by binding to highly conserved target
sites in its 3′UTR.
& Expression of miR-20a is inversely correlated to FPN in
lung cancer.
& Low FPN expression stimulates proliferation and colony
formation of non-small cell lung cancer (NSCLC) cells,
possibly by increasing iron availability for cancer cell
proliferation.
Keywords Ferroportin . miR-20a . Lung cancer .
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Introduction
MicroRNAs (miRNAs) are a class of small non-coding RNAs
that negatively regulate gene expression by base pairing to
partially complementary sites within the 3′-untranslated re-
gions (3′UTR) of target messenger RNAs (mRNA) [1].
Binding of miRNA to its target mRNA causes translation
repression [2] and/or mRNA degradation [3]. Genome-wide
profiling of miRNA expression in cancer samples and their
corresponding normal tissues showed a distinguished signa-
ture between tumoral and normal cells [4, 5], which is often
associated with cancer prognosis and progression [6–8]. In
particular, a well-characterized polycistronic miRNA cluster,
the miR-17-92 family, accomplishes pleiotrophic functions in
cancer [9, 10]. It is highly conserved among vertebrates [11]
and has two mammalian paralogs: the miR-106a-363 and the
miR-106b-25 cluster [12]. The miRNAs encoded by miR-17-
92 and its two paralogs can be categorized into four Bseed^
families according to their seed sequences: miR-17 family
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(including miR-17, miR-20a, miR-20b, miR-106a, miR-106b
and miR-93), miR-18 family (miR-18a and miR-18b), miR-
19 family (miR-19a, miR-19b-1 and miR-19b-2), and miR-92
family (miR-92a-1, miR-92a-2, miR-25, and miR-363) [13].
Overexpression of the miR-17-92 cluster has been observed in
a variety of hematological malignancies and solid tumors in-
cluding B cell lymphoma, B cell chronic lymphocytic leuke-
mia (CLL), retinoblastoma, meduloblastoma, osteosarcoma,
and cancers of the colon, pancreas, breast, lung, kidney, and
liver (as reviewed in [13]). The miRNA members of the miR-
17-92 cluster contribute to cancer pathogenesis by directly
regulating genes associated with cell growth and proliferation.
The miR-17 family (miR-17 and miR-20a) triggers rapid pro-
liferation by repressing the cell cycle inhibitors p21
(CDKN1A) and p57 (CDKN1C) [14, 15] as well as by direct-
ly targeting the proapoptotic protein Bim (BCL211) [16] and
the tumor suppressor gene phosphatase and tensin homolg
(PTEN) [17]. Furthermore, they also regulate genes that mold
the conditions for cellular proliferation. miR-17-92 blocks the
production of transforming growth factor (TGF)-β-dependent
antiangiogenic factors through suppressing the TGF-β recep-
tor II (TGFBRII), Smad2, and Smad4 [18] whereas miR-18a
and miR-19 promotes angiogenesis by directly targeting
thrombospondin 1 (TSP-1) and connective tissue growth fac-
tor (CTGF), respectively [19].
Iron is essential for various cellular processes, including
cell proliferation and growth. It plays a crucial role in DNA
synthesis as it is mandatory for the iron-dependent enzyme
ribonucleotide reductase that catalyzes the formation of de-
oxyribonucleotides from ribonucleotides [20], as well as for
the regulation of molecules involved in cell cycle control such
as p53, GADD45, and CDKN1A [21–24]. Cellular iron avail-
ability is regulated by a growing network of genes that main-
tain cellular iron acquisition, storage, utilization, and export
[25]. Among these, ferroportin (FPN) is the only knownmam-
malian iron exporter. It is predominantly expressed in cell
types that export iron to the blood stream, including duodenal
enterocytes that take up iron from the diet, iron-recycling
macrophages, and hepatocytes that store iron. In addition,
most cell types express low levels of FPN, including cancer
cells [26].
FPN expression is regulated at the transcriptional level by
hypoxia-inducible factor-2alpha (HIF2α) in response to hyp-
oxia and iron deficiency [27] as well as by BACH1 and Nrf2
in response to excess heme or oxidative stress [28, 29]. At the
translational level, its expression is controlled by iron regula-
tory proteins (IRPs) that bind to an iron responsive element
(IRE) located in its 5′UTR [30]. At the post-translational level,
binding of the hepatic iron hormone hepcidin (HAMP) trig-
gers its internalization, ubiquitination, and subsequent lyso-
somal degradation [31, 32]. In recent years, several examples
emerged that genes involved in maintaining iron homeostasis
are controlled by miRNAs [33]. For example, the liver
specific miR-122 indirectly regulates expression of HAMP
by directly targeting two of its upstream activators: the human
hemochromatosis protein (HFE) and hemojuvelin (HJV) [34].
In addition, transferrin receptor 1 (TFR1) is negatively regu-
lated by miR-210 and miR-320 causing decreased transferrin
uptake and inhibition of proliferation of lung adenocarcinoma
A549 cells [35, 36]. miR-let-7d represses expression of an
isoform of divalent metal transporter 1 (DMT1) causing accu-
mulation of iron in endosomes of K562 erythroleukemia cells
[37]. Finally, miR-485-3p regulates cellular iron homeostasis
by directly targeting FPN [38].
In this study, we show that the FPN-3′UTR contains highly
conserved and functional target sites for miR-20a, a member
of the miR-17 seed family. Our analyses of high-throughput
RNA sequencing datasets from The Cancer Genome Atlas
(TCGA) revealed that expression of miR-20a is significantly
increased in patients with lung adenocarcinoma (LUAD) and
lung squamous cell carcinoma (LUSC) and correlates with
decreased expression of FPN. Overexpression or knockdown
of miR-20a in the non-small cell lung cancer cell lines
(NSCLC) H1299 and H1650 significantly affects FPN expres-
sion post-transcriptionally. Importantly, low FPN expression
stimulates proliferation and colony formation of NSCLC cells,
possibly by increasing iron availability for cancer cell
proliferation.
Materials and methods
Cell culture and reagents
Huh7 and NSCLC cell lines were cultured in DMEMmedium
(Invitrogen), supplemented with 10 % FBS (Invitrogen). Cell
cultures were maintained at 37 °C under 5 % CO2. Hepcidin
(HAMP) was applied at the concentration of 1 μg/mL (peptide
institute).
RNA isolation, reverse transcription, and quantitative
real-time PCR
Total RNA including miRNA was isolated using the
miRNeasy Micro Kit (Qiagen) according to the manufac-
turer’s instructions. mRNAs were reverse transcribed to com-
plementary DNA (cDNA) using the RevertAid RT Reverse
Transcription Kit (Thermo Scientific), and miRNAs were re-
verse transcribed using the miScript II RT kit (Qiagen).
Quantification of mature miRNA was performed by using
the miScript SYBR-Green PCR kit (Qiagen). SYBR green
real-time PCR was performed to quantify mRNA expression
levels using the ABI StepOne Plus Real-Time PCR system
(Applied Biosystems). mRNA and miRNA expression was
calculated relative to ACTB and RNU6, respectively. Data
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were analyzed using theΔΔCtmethod [39]. The primers used
are listed in the Table S1.
Plasmid cloning and site-directed mutagenesis
To generate the pcDNA FPN-enhanced green fluorescent
protein (EGFP) construct, the complete human FPN coding
sequence was amplified from cDNA of HEK293 cells and
inserted into the NheI-XheI restriction sites of the pEGFP-
N1 vector (Clontech). To generate the pcDNA FPN-flag con-
struct, the EGFP sequence at the EcoRI-NotI site of the
pEGFP-N1 vector was replaced by double-stranded DNA
oligo nucleotides containing the flag sequence. Primer se-
quences are listed in Table S2. The complete 3′UTR segments
of the human HIF1A and FPN were amplified by PCR from
genomic DNA of Huh7 cells and inserted into the pmirGLO
Dual-Luciferase miRNATarget Expression Vector (Promega).
In addition, a double-stranded DNA oligo nucleotide
encompassing the complete 3′UTR of RPL19 was directly
inserted into the vector (pMIR-RPL19). To generate a positive
(pMIR-20a+) and a negative (pMIR-20a−) control vector, a
double-stranded DNA oligo nucleotide with the identical se-
quence of miR-20a was inserted into the pmirGLO vector
either in the sense (+) or antisense (−) orientation. Double-
stranded DNA oligo nucleotides were annealed in oligo an-
nealing buffer (Promega). Primer sequences are listed in
Table S3. Site-directed mutagenesis of the predicted miR-
20a seed sequence within the 3′UTR of the genes of interest
was performed using the QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent Technologies) following the manu-
facturer’s protocol. Primers are listed in Table S4. All the
constructs were confirmed by plasmid DNA sequencing.
Dual-luciferase reporter assay
Huh7 cells (5×103 cells/well) were plated on a sterile 96-well
assay plate (Corning), and after 24 h, cells were transfected
with 50 nM of miR-20a mimic or a negative control (NC)
(Ambion) using RNAiMAX reagent (Invitrogen). After
24 h, 10 ng of luciferase constructs were transfected using
Lipofectamine 2000 reagent (Invitrogen). Twenty-four hours
later, cells were lysed using 1× passive lysis buffer (Promega),
and cellular extracts were analyzed for luciferase activity
using the Dual Luciferase Reporter assay system (Promega)
and the Centro LB 960 luminometer (Berthold Technologies).
Cell proliferation and colony-forming assay
To determine proliferation, 30×103 cells per well were seeded
in a 24-well culture plate in complete growth media.
Following trypsinization, cell numbers were determined at
the interval of 24 h for 6 days in a hemocytometer. For the
colony-forming assay, H1299 cells (1×103) were seeded in a
6-well culture plate in complete growth medium. After incu-
bation for 15 days, the colonies were fixed with methanol for
5 min and stained with crystal violet for 15 min, colonies were
counted using the Cell Counter v.2.1, a colony counting
software.
Western blot analysis and flow cytometry
Cells were harvested and lysed on ice for 30 min in RIPA
buffer supplemented with protease inhibitors (Roche).
Antibodies directed against ACTB (Sigma) and FLAG
(Sigma) were used. Protein concentration was determined
using the DC protein assay (BioRad). Western blot images
were acquired using the Fusion-Fx system (Vilber Lourmat).
Flow cytometry analysis was done using the BD LSRFortessa
cell analyzer (BD Biosciences).
miRNA expression atlas, target prediction, and TCGA
RNA-seq datasets
miRNA expression atlas was generated using MiRZ
(https://www.mirz.unibas.ch) [40]. Potential miRNA targets
were predicted and analyzed using four publically available
algorithms: miRanda (http://www.microrna.org), TargetScan
(http://www.targetscan.org), PicTar (http://pictar.mdc-berlin.de)
, and RNA22 (https://cm.jefferson.edu/rna22/). TCGA RNA-
seq datasets from cancer subtypes including LUAD, LUSC,
breast cancer (BRCA), and liver hepatocellular carcinoma
(LIHC) were downloaded from the publically available UCSC
Cancer Genomics Browser (https://genome-cancer.ucsc.edu/)
[41].
Transfection of siRNAs, miRNA mimics/inhibitors,
and plasmids
FPN short interfering RNAs (siRNAs) (Ambion), miR-20a
mimics, or inhibitors (Ambion) were transfected using
Lipofectamine RNAiMAX Reagent (Invitrogen), while plas-
mid vectors (pmirGLO, pcDNA) were transfected using the
Lipofectamine 2000 reagent (Invitrogen).
Statistical analysis
Data are represented as means±SEM of at least three indepen-
dent experiments. The results were analyzed using Prism v.6
(GraphPad). Two-tailed Student’s t test was applied for testing
the significance for quantitative real-time PCR (qRT-PCR)
data and colony formation assays and the two-way ANOVA
test for cell proliferation. Pearson’s correlation coefficient was
applied to analyze the correlation between expression levels of
miRNAs and FPN. Values were considered significantly dif-
ferent when P<0.05.
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Results
Identification of conserved target sites for members
of the miR-17 seed family within the FPN-3′UTR
To investigate whether the FPN-3′UTR contains miRNA
binding sites, we screened the entire 3′UTR sequence of
human FPN (1286 nt) using a combination of miRNA
target prediction algorithms: miRanda [42], Targetscan
[43], PicTar [44], and RNA22 [45]. We next selected only
those miRNAs that showed conserved homologues in hu-
man and mouse and that were predicted by all algorithms
applied. Among these, we identified three putative miR-17
family target sequences (Fig. 1a). The miR-17 family
consists of six miRNA members (miR-17, miR-20a/b,
miR-93, and miR-106a/b) all sharing conserved seed se-
quences between human and murine homologues
(Fig. 1b). As a representative of the miR-17 family, we
chose miR-20a for subsequent investigations. miR-20a tar-
get sequences within the human FPN-3′UTR are located at
nt 1108–1114, nt 1132–1138, and nt 1166–1172 (Fig. 1c).
Interestingly, two of the putative miR-20 binding sites
within the FPN-3′UTR sequence are highly conserved
among ten species, while the miR-20a target sequence at
nt 1108–1114 is conserved among six species (Fig. 1d).
Together, these bioinformatic analyses suggest that miRNA
members of the miR-17 family might target highly con-
served binding sites within the FPN-3′UTR.
Fig. 1 Identification of highly conserved target sites for members of the
miR-17 seed family within the FPN-3′UTR. a Schematic illustration of
the selection process of miRNAs that target the FPN-3′UTR. bMembers
of the human and mouse miR-17 seed family possess highly conserved
seed sequences (bold faced). c miR-20a binding sites reside at nt 1108–
1114, nt 1132–1138, and nt 1166–1172 of the FPN-3′UTR (bold faced). d
Sequence alignment between the miR-20a seed sequence and its target
sites (bold faced) within the FPN-3′UTR of ten mammalian species
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miR-20a downregulates FPN expression by directly
targeting the FPN-3′UTR
To investigate whether miR-20a directly targets FPN by bind-
ing to the bioinformatically predicted miR-20a binding sites
within its 3′UTR, we generated luciferase reporter constructs
bearing the full 3′UTR sequence of human FPN (referred
herein as pMIR-FPN) or constructs with mutated miR-20a
target sites (Fig. S1B) to assess the specificity of miR-20a-
dependent FPN regulation. As a negative control, we inserted
the complete 3′UTR of the human RPL19 gene within the
same vector (pMIR-RPL19), which does not have predicted
miR-20a target sites. As a positive control, we cloned the 3′
UTR of the human HIF1A gene (pMIR-HIF1A), which is a
validated miR-20a target, or of a mutant derivative (Fig. S1A)
[46]. In addition, artificial positive and negative control vec-
tors with perfect sequence complementary tomiR-20a or iden-
tical to miR-20a (pMIR-20+ and pMIR-20−, respectively)
were studied. miR-20a mimics were transfected together with
the luciferase reporter plasmids into Huh7 human
hepatocarcinoma cells. Upon miR-20a overexpression, lucif-
erase activity from cells transfected with the positive control
plasmids pMIR-20+ and pMIR-HIF1A was strongly reduced
whereas luciferase activity was unaffected from cells
transfected with the negative control plasmids pMIR-20−,
pMIR-HIF1A-MUT, or pMIR-RPL19 (Fig. 2a), suggesting
that miR-20a overexpression is efficient and specific.
Importantly, overexpression of the miR-20a mimic signifi-
cantly reduced luciferase activity of pMIR-FPN but not of
pMIR-FPN-MUT, in which predicted miR-20a target sites
were mutated (Fig. 2a). To further investigate whether over-
expression of miR-20a negatively regulates endogenous FPN
mRNA expression, we analyzed FPN mRNA levels from
miR-20a mimic-transfected Huh7 cells. We show that
mRNA levels of FPN and HIF1A (positive control) were sig-
nificantly reduced upon miR-20a overexpression (Fig. 2b)
whereas mRNA levels of RPL19 (negative control) remained
unaffected (Fig. 2c). Taken together, our data show that miR-
20a directly targets the FPN-3′UTR and negatively regulate
FPN mRNA levels.
Expression of miR-20a is inversely correlated to FPN
in lung cancer
We next explored the clinical relevance of interactions be-
tween miR-20a, a member of the oncogenic miR-17-92 clus-
ter that is frequently deregulated in cancer [13], and FPN by
correlating RNA expression data from cancer patients. We
limited our analysis to high-quality RNA-seq data sets avail-
able within TCGA (http://cancergenome.nih.gov/) from
patients with LUAD, LUSC, BRCA, and LIHC. RNA-seq
datasets was chosen to be able to differentiate the expression
of each miRNA member of the highly conserved miR-17
family. We found that mRNA expression of FPN is signifi-
cantly inversely correlated with that of miR-20a (P<0.0001)
in LUAD patients (n=524) (Fig. 3a) and in the LUSC patients
(n=513) (Fig. 3b). Our analysis further revealed that in
LUAD, the expression of miR-20a was significantly elevated
(P<0.0001) in tumor compared to matched healthy tissue
from the same patient (Fig. 3c). Conversely, the mRNA ex-
pression of tissue FPN was significantly decreased (P<0.
0001) (Fig. 3d). Similar results were obtained by comparing
tumor samples of LUSC patients, in which miR-20a was sig-
nificantly overexpressed (P=0.0003) in tumor tissue (Fig. 3e),
while FPN mRNA expression was significantly decreased in
matching healthy tissue (P<0.0001) (Fig. 3f). Moreover, the
expression of other miR-17 family members, except of miR-
20b was also significantly increased in tumors of LUAD and
LUSC patients (Fig. S2). Correlation analyses of FPN mRNA
expression and expression levels of miR-17 seed family mem-
bers revealed that in LUAD patients, FPN mRNA expression
was negatively correlated to all six miRNAs of the miR-17
family (Fig. 3a and S3A). By contrast, in LUSC and in LIHC,
FPN mRNA expression was significantly negatively correlat-
ed to miR-17, miR-20a, miR-106b, and miR-93 expression
levels but not to miR-106a and miR-20b (Fig. 3b, S3B and
S4A). Likewise, in BRCA, we found that FPN expression was
negatively correlated to miR-17 miRNA members except
miR-20b (Fig. S4B). Collectively, these data suggest that
overexpression of miR-20a might be involved in regulating
FPN mRNA levels in several cancer subtypes, including lung
cancer.
FPN is post-transcriptionally regulated by miR-20a
in NSCLC
To further explore the relationship of miR-20a and FPN ex-
pression in lung cancer, a total of five NSCLC cell lines (H23,
H838, H1299, H1650, and H1975) were analyzed for the
expression of premature mRNA (pre-mRNA) of FPN to iden-
tify cell lines that show comparable levels of FPN transcrip-
tion. We show that pre-mRNA levels of FPN in the five
NSCLC cell lines differed significantly, whereby FPN pre-
mRNA expression (P=0.7981) was similar between H1299
and H1650 cells (Fig. 4a). Analysis of FPN mRNA and miR-
20a expression in the H1299 and H160 cell lines showed that
expression of FPN mRNA in H1650 was significantly higher
compared to H1299 (Fig. 4b) whereas the inverse result was
obtained for miR-20a (Fig. 4c). Next, we examined whether
manipulation of miR-20a levels could affect the expression of
FPN mRNA in NSCLC cell lines. We transfected miR-20a
inhibitors into H1299 or miR-20a mimics into H1650 in order
to reduce or increase miR-20a levels, respectively, and then,
we analyzed the levels of miR-20a and FPNmRNA by qPCR.
We observed that miR-20a levels were significantly reduced
in miR-20a inhibitor-transfected H1299 cells (Fig. 4d)
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confirming successful knockdown of miR-20a. At the same
time expression of FPN mRNA was significantly increased
(Fig. 4e). Likewise, levels of miR-20a were significantly in-
creased in the miR-20a mimic-transfected H1650 cells
(Fig. 4f) implying successful overexpression of miR-20a,
whereby FPN mRNA expression was reduced (Fig. 4g).
These results suggest that miR-20a regulates FPN expression
post-transcriptionally in NSCLC.
miR-20a and FPN expression control NSCLC
proliferation and colony formation
We next assessed the potential pathological relevance of miR-
20 and FPN expression in NSCLC. Previous studies showed
that overexpression of miR-20a promotes lung cancer cell
proliferation [47] and that overexpression of FPN reduces
breast tumor growth in mice [48]. Thus, we hypothesized that
expression levels of miR-20a and FPN could alter the rate of
cell proliferation. To manipulate miR-20a levels, we either
transiently transfected miR-20a inhibitors or miR-20a mimics.
FPN expression was increased by transfecting the vector
pcDNA FPN-flag into H1299 cells, which expresses a flag-
tagged FPN (Fig. 5b). Expression of a tagged FPN protein
version is required, as sensitive antibodies directed against
human FPN are unavailable. The transfection rate of H1299
cells is close to 100 %, as was estimated by transiently
transfecting H1299 cells with a vector in which FPN is fused
to EGFP (pcDNA FPN-EGFP) (Fig. S5). Importantly,
overexpressed FPN is localized to the cell membrane in
pcDNA FPN-flag transfected H1299 cells, because treatment
with the iron hormone hepcidin efficiently reduces FPN pro-
tein levels (Fig. 5b).
The proliferation rate of transiently transfected cells was
analyzed by counting cell numbers in a hemocytometer for
6 days. We show that inhibition of miR-20a in H1299 cells
represses cell proliferation (F(6,28)=4.157; P=0.0041)
(Fig. 5d), while in miR-20a mimic-transfected H1650 cells,
proliferation was significantly increased (F(6,28)=7.153; P=
Fig. 2 Validation of FPN as a target gene of miR-20a. Huh7 cells were
transfected with 50 nM of miR-20a mimic or a negative control (NC).
Twenty-four later, a the luciferase reporter constructs pMIR-20+ (miR-
20a complementary sequence), pMIR-20− (identical sequence of miR-
20a), pMIR-RPL19, pMIR-HIF1A, pMIR-HIF1A-MUT, pMIR-FPN, or
pMIR-FPN-MUT were transfected (MUT mutated miR-20a or HIF1A
target sites, see Fig S1). Luciferase activity was measured 48 h later. b
To test specific and efficient transfection of miR-20a, we measured miR-
21 and miR-20a levels by qPCR. c mRNA expression of RPL19
(negative control), HIF1A (positive control), and FPN were measured
by qPCR. Experiments were performed in triplicates and repeated at
least three times. Data were normalized to appropriate reference genes:
RNU6 (b) and ACTB (c). Data are represented as mean±SEM, and the
values from negative control (NC) mimic were set to 100% (a) or 1 (b, c)
*P<0.05, **P<0.001, ***P<0.001, ****P<0.0001, two-tailed
Student’s t test
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0.0001) (Fig. 5f). Furthermore, FPN-flag overexpression in
transfected H1299 cells decreased cell proliferation (F(6,
28)=5.369; P=0.0009) (Fig. 5e). By contrast, transfection of
two different siRNAs that efficiently reduce FPN mRNA and
protein levels (Fig. 5a–c) increased cell proliferation of H1650
cells: FPN siRNA1 (F(6,28)=5.047; P=0.0013) (Fig. 5g) and
FPN siRNA2 (F(6,28)=4.335; P=0.0033) (Fig. 5h). Similar
results were obtained when FPN protein levels were reduced
by treatment with HAMP (1 μg/mL) in the growth medium
(F(6,28)=3.393; P=0.0121) (Fig. 5i).
Reduced FPN expression decreases the capacity for iron
export and causes cellular iron retention. As a marker for
cellular iron content, we analyzed mRNA levels of transferrin
receptor (TFR1). Its expression is regulated by the IRP/IRE
system [49] in that mRNA levels are increased by cellular iron
deficiency and decreased when cellular iron levels are elevat-
ed. TFR1 mRNA expression in H1650 cells either transfected
with miR-20a mimic or siRNA directed against FPN is sig-
nificantly reduced in a time-dependent manner (Fig. S7), sug-
gesting that the observed reduction in FPN mRNA levels
causes reduced iron export and iron accumulation in cells.
By applying similar experimental approaches, we next
assessed whether miR-20a and FPN expression levels can
affect NSCLC colony formation. H1299 cells were transiently
transfected with miR-20a mimics/inhibitors or pcDNA FPN-
flag/FPN siRNA, respectively. Twenty-four hours later, the
transfected cells were seeded in 6-well plates at a defined
clonal density (1000 cells/well), and 15 days later, the number
of colonies were counted. Interestingly, both the knockdown
of miR-20a and overexpression of FPN-flag significantly
Fig. 3 mRNA expression of FPN is inversely correlated to the
expression of miR-20a in lung cancer. TCGA RNA-seq datasets of lung
adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)
patients were downloaded from the UCSC cancer genomic browser
(https://genome-cancer.ucsc.edu) [41]. Correlations between miR-20a
and FPN expression levels are represented as scatter plots for a LUAD
(n=524, r=−0.308, P<0.0001) and b LUSC (n=513, r=−0.386, P<0.
0001), Pearson’s product moment correlation was used. Box plots
illustrate that in patients with LUAD, c miR-20a is significantly
elevated (n=45, P<0.0001) while d FPN mRNA expression is
significantly decreased (n=57, P<0.0001) compared to matched normal
healthy tissues. Similarly, in patients with LUSC, e miR-20a is
significantly increased (n=44, P=0.0003) whereas f FPN is
significantly decreased (n=49, P<0.0001), two-tailed Student’s t test,
RPKM reads per kilobase per million mapped reads
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decreased the capacity to form colonies, whereby the knock-
down of miR-20a showed a stronger effect compared to FPN-
flag overexpression (P=0.0152) (Fig. 6a). Vice versa, overex-
pression of miR-20a and RNAi of FPN significantly increased
the colony-forming capacity, whereby overexpression of miR-
20a showed stronger effects compared to RNAi of FPN (P=
0.0205) (Fig. 6b). Taken together, our data show that miR-20a
controlled FPN expression contributes to increase cellular pro-
liferation as well as the capacity of NSCLC to form colonies.
Discussion
This study identifies FPN as a target of miR-20a. miR-20a-
dependent FPN regulation enhances the rate of cancer cell
proliferation and the capacity to form colonies. The FPN 3′
UTR contains three evolutionarily conserved, functional tar-
get sites for the highly homologous miR-17 seed family
miRNA members (Fig. 1). Two miR-17-5p target sites at nt
1132–1138 and nt 1116–1172 within the FPN-3′UTR were
predicted by a recent study, but the functionality was not prov-
en [50]. The same study predicted a target site for miR-17-3p,
the passenger strand of miR-17 at nt 61–67, suggesting that
FPN may also be targeted by passenger strands of miR-17
seed family members. Another study showed that cellular iron
deprivation induces miR-485-3p, which regulates FPN by di-
rectly targeting sites within the FPN-3′UTR at nt 448–454 and
nt 618–625 [38]. These findings suggest that miRNAs may
play important roles in regulating FPN expression in physio-
logical and pathophysiological condition. This adds an addi-
tional level of complexity to the control of FPN expression,
which was previously shown to be regulated at the transcrip-
tional, translational, and post-translational level [27–29, 31,
32, 51].
Here, we demonstrate for the first time that elevated miR-
20a levels suppress expression of endogenous FPN mRNA in
Fig. 4 FPN is post-transcriptionally regulated by miR-20a in non-small
cell lung cancer (NSCLC) cells. a A total of five NSCLC were analyzed
for FPN pre-mRNA levels by qPCR. Insignificant differences of FPN
pre-mRNA expression were only observed between H1299 and H1650
(P=0.7981). b FPN mRNA expression and c miR-20a expression in the
H1299 and H1650 cell lines. H1299 cell were transfected with 50 nM of
miR-20a inhibitors or a negative control (NC). Twenty-four hours later,
the expression of miR-20a (d, f) and FPN (e, g) mRNAwere analyzed by
qPCR. Experiments were performed in triplicates and repeated at least
three times. Data were normalized to appropriate reference genes: ACTB
(a, b, e, g) or RNU6 (c, d, f). Data are represented as mean±SEM, and the
values from negative controls (NC)mimic or inhibitor were set to 1. ns no
statistical significance, *P< 0.05, **P< 0.01, ***P< 0.001,
****P<0.0001, two-tailed Student’s t test
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Fig. 5 Alteration of miR-20a or FPN expression affects NSCLC
proliferation. H1299 cells were transiently transfected with either miR-
20a inhibitor, a negative control (NC), the expression plasmid pcDNA
FPN-flag, or a control vector (pcDNA empty). H1650 cells were
transiently transfected with either miR-20a mimic, a negative control
(NC), specific FPN siRNAs (FPN siRNA 1 and FPN siRNA 2) or NC
siRNA. a FPN mRNA levels analyzed by qPCR in H1650 cells. qPCR
data were normalized to ACTB. ****P<0.0001, two-tailed Student’s t
test. b, cWestern blot analysis of FPN protein levels following RNAi or
overexpression of FPN in H1299 cells. c Time course experiment
showing the effects of FPN overexpression or knockdown on cell
proliferation for up to 5 days. d–i Proliferation assays performed in
H1299 cells (d, e) or H1650 cells (f–i) in response to the indicated
treatments. All experiments were performed in triplicates and repeated
at least three times. Data represented as mean±SEM. Two-way ANOVA
was applied to calculate statistical significance of proliferation curves.
*P<0.05, **P<0.01, ***P<0.001
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cell lines (e.g., Huh7 and H1650) (Fig. 2c and 4g), while
reduced miR-20a levels increase expression of endogenous
FPNmRNA (Fig. 4e). Unfortunately, sensitive antibodies that
detect human FPN are unavailable, hampering analysis of
endogenous FPN protein expression. We therefore validated
the bioinformatically predicted miRNA target sites by
transfecting cells with luciferase reporter constructs that con-
tain the entire FPN-3′UTR. Our experiments show that lucif-
erase activity is altered in a miR-20a-dependent manner that
requires the predicted target sequences within the FPN-3′UTR
(Fig. 2a).
Our analysis further uncovered a significant negative cor-
relation between mRNA expression levels of FPN and mem-
bers of the miR-17 seed family in several cancer subtypes,
including lung, breast, and liver cancer (Fig. 3, S3, S4).
While correlations were strong for most miR-17 seed family
members, including miR-20a, it was not apparent for miR-
106a and miR-20b, which are expressed from the miR-106a-
363 cluster at very low levels [52]. These findings suggest
that miR-20a and miRNAs with identical seed sequences
reduce levels of the iron exporter FPN in various human
cancer subtypes. We further observe that FPN levels are
decreased in two lung cancer subtypes (LUAD and LUSC;
Fig. 3d, f, respectively) compared to healthy lung tissue.
This is reminiscent of observations in breast cancer, colorec-
tal cancer, and multiple myeloma. In addition, lower expres-
sion of FPN is linked to poor survival in breast cancer and
in multiple myeloma [48, 53–55]. Our results extend upon
these observations by demonstrating that manipulation of
FPN levels directly or mediated by alteration of miR-20a
or treatment with hepcidin affects cancer cell proliferation
(Fig. 5) and colony formation (Fig. 6). It is of note that in
our cellular assays, changes in miR-20a levels triggered by
transfection with either miR-20a inhibitor or mimic are more
pronounced than those observed between normal and tumor
tissues in TCGA RNA-sequencing datasets of LUAD and
LUSC (Fig. 3c–f). Whether the small changes in FPN
mRNA levels in tumor tissues are sufficient to alter FPN
protein expression and iron metabolism is not clear.
In addition to FPN, miR-20a targets additional genes,
which are involved in cell cycle control and growth
[13]. This is evidenced by the fact that miR-20a manip-
ulation affects colony formation more strongly compared
to direct alterations of FPN levels (Fig. 6). This sug-
gests that differences of miR-20a expression will affect
FPN plus additional target genes involved in cell cycle
and growth causing cumulative effects on cell prolifer-
ation and colony formation (Figs. 5 and 6).
Fig. 6 Colony formation of
H1299 cells is affected by
expression levels of miR-20a and
FPN. H1299 cells were
transiently transfected with either
a miR-20a mimic, a miR-20
inhibitor, pcDNA FPN-flag, or
FPN siRNA. Twenty-four hours
later, the cells were seeded at a
clonal density of 1000 cells/well
in a 6-well plate. After 15 days of
incubation, the colonies were
counted using the Cell Counter
v.2.1. Quantitative data are shown
in a and b. Treatments are
indicated. Left, representative
pictures of colonies formed; right,
quantitation of colonies.
Experiments were performed in
triplicates and repeated at least
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Furthermore, the oncogenic miR-20a may control iron me-
tabolism indirectly, e.g., by modulating the expression levels
of the transcription factor HIF1A (Fig. 2a, c) [46, 56]. As the
hypoxic response and regulation of iron metabolism are tight-
ly interconnected [57], HIF1A may be involved in regulating
genes that maintain iron homeostasis, e.g., transferrin, TFR1,
ceruloplasmin, and heme oxygenase 1 in cancer [58–64].
miR-17 family members also directly target the amyloid pre-
cursor protein (APP) [65, 66] that was hypothesized to exert
ferroxidase activity and to facilitate iron export by stabilizing
FPN [67, 68].
Two different miRNAs, miR-20a and miR-485, control
FPN expression (data shown here and [38]). Therefore, we
additionally analyzed miR-485 and FPN expression in RNA
sequencing data from LUAD and LUSC patients. Similar to
our findings with miR-20a, miR-485 expression negatively
correlates to FPN mRNA expression (Fig. S6A and B).
Despite that miR-485 expression was only significantly in-
creased in tumors of LUSC but not in LUAD (Fig. S6C, E).
These findings are consistent with previous reports that show
roles for forced miR-485-3p expression in promoting tumori-
genesis and metastasis in mice [69], indirectly affecting sen-
sitivity to etoposide and fludarabine by fine tuning DNA
Topoisomerase II expression via nuclear factor-YB [70, 71]
and by regulating methionine adenosyltransferase 1A expres-
sion in hepatocellular carcinoma [69]. It is of note that miR-
20a is significantly higher expressed compared to miR-485 in
lung cancer (Fig. S6D, F) as well as in most other tissues or
cell types analyzed (Fig. S8). This may suggest that miR-485
and miR-20a cooperate in regulating FPN levels in lung can-
cer, but that the regulatory effect of miR-20a on FPN may
dominate over the one of miR-485 due to its low expression
level.
How is the alteration of FPN levels linked to cell prolifer-
ation and tumor growth? Previous findings showed that
changes in FPN expression affect the labile iron pool (LIP)
[31, 48, 54] and thus will influence intracellular availability of
this important nutrient. In addition, the treatment of cells with
iron chelators that limit iron supplies arrest the cell cycle be-
tween the G1/S phase or in some instances between the G2/M
phase [72–74], suggesting that cell cycle check points exist
that monitor iron levels. Iron chelation was therefore tested as
an anticancer therapy [26, 75].
Taken together, these findings suggest that manipulation of
FPN expression may cause changes in intracellular iron avail-
ability in NSCLC cells that influence the rate of cell prolifer-
ation. Increased expression of miR-20a, which is observed in
diverse tumor entities will decrease FPN levels and retain iron
in tumor cells, in addition to regulating numerous other genes
involved in cell proliferation and growth [13, 76, 77]. In ad-
dition, in cancer cells, other genes involved in maintaining
cellular iron homeostasis are differentially expressed. These
include genes involved in iron acquisition (e.g., TFR1) [78] or
iron storage [79, 80], which are directly or indirectly regulated
by oncogenes like MYC or HRAS [81, 82].
In conclusion, our results strongly suggest that the
downregulation of FPN by the oncogenic miR-20a, which
is overexpressed in various cancer entities, may cause an
increase in the cellular labile iron pool thus providing
surplus iron for metabolic processes like DNA synthesis
or the proliferation or growth of cancer cells. Overall,
post-transcriptional regulation of FPN by miR-20a may
act as a contributing factor to cancer prognosis making
FPN a potential target for anticancer therapy.
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